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The immediate–early 2 (IE2) protein of human herpesvirus 6 (HHV-6) is a potent transactivator of multiple cellular and viral promoters.
Deletion mutants of HHV-6 variant A IE2 allowed us to map functional transactivation domains acting on complex and minimal promoter
sequences. This mapping showed that both the N-terminal and C-terminal domains of IE2 are required for efficient transactivation, and that deletion
of the C-terminal (1397–1466) tail of IE2 drastically reduces both transactivation and the intranuclear distribution of IE2. Moreover, we determined
that the ATF/CRE binding site within the HHV-6A polymerase promoter is not required for efficient transactivation by IE2, whereas the R3 repeat
region of the putative immediate–early promoter of HHV-6A is responsive to and positively regulated by IE2. These results contrast sharply to that
of human cytomegalovirus (HCMV) IE2, which down-regulates its promoter. Our characterization of HHV-6 IE2 transactivating activity provides a
better understanding of the complex interactions of this protein with the viral and cellular transcription machinery and highlights significant
differences with the IE2 protein of HCMV.
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Human herpesvirus 6 (HHV-6) is a betaherpesvirus initially
isolated from human immunodeficiency virus (HIV)-infected
individuals and from patients suffering from lymphoprolifera-
tive disorders (Salahuddin et al., 1986). Two HHV-6 variants (A
and B) have been identified. Although they share a high degree
of homology for the majority of their genes (95–99%), these two
variants are considered distinct infectious agents in view of their
biological properties (such as gene expression and splicing
pattern, in vitro cell tropism, reactivity to monoclonal anti-
bodies), tissue distribution and disease association (Ablashi et
al., 1991). The greatest genetic variability between the two
HHV-6 variants is observed within the immediate–early 1 and 2
genes (60–70% amino acid identity), variations that may⁎ Corresponding author. Fax: +1 418 654 2765.
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6B is the etiologic agent of the childhood disease roseola or
exanthema subitum (Yamanishi et al., 1988). Links between
HHV-6 infection and other pathologies such as meningo-
encephalitis (Ishiguro et al., 1990), organ transplant rejection
(Carrigan et al., 1991; Yoshikawa et al., 1991) and AIDS (Knox
and Carrigan, 1995; Saito et al., 1995) have also been suggested.
Evidence for a co-factorial role of HHV-6A in AIDS come from
several observations, including that co-infection of T cells with
HIV and HHV-6 leads to the activation of HIV long terminal
repeat (LTR)-directed viral gene expression and accelerates
cytopathic effects (Lusso et al., 1989).
Several HHV-6 gene products have been identified as
potential transcriptional activators. Among them, products of
open reading frames (ORFs) DR7 (Thompson et al., 1994a,
1994b), U16 (Geng et al., 1992), U27 (Zhou et al., 1994), U90/
U86 (Gravel et al., 2003), U89 (Martin et al., 1991) and U94
(Thompson et al., 1994a, 1994b) were found to transactivate the
HIV LTR promoter in vitro. ORFs U86 and U89 are comprised
within the HHV-6 immediate–early A (IE-A) locus. IE-A
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ORFs U90/U89 and U90/U86, respectively (Fig. 1A). We have
previously characterized the IE1 variant B (Gravel et al., 2002)
and IE2 variant A (Gravel et al., 2003) proteins translated from
spliced transcripts of the IE-A locus.
It has been reported that the IE2 protein is a potent
transcriptional activator of heterologous promoters (Flamand
et al., 1998; Gravel et al., 2003). Moreover, cotransfection
experiments in T cells indicated that IE2 variant A can induce
the transcription of a complex promoter such as the one present
in the HIV LTR, as well as simpler promoters, whose expression
is driven by a unique set of responsive elements (CRE, NF-AT,
NF-κB) (Duprez et al., 1999; Gravel et al., 2003). Finally, the C-
terminal domain encompassing the final 436 residues of HHV-
6A IE2 was shown to bind a DNA fragment containing the
transcription initiation site, TATA box and upstream sequence
of the putative IE-A promoter (Papanikolaou et al., 2002).
Transcriptional activators must possess at least two func-
tional domains: a DNA binding domain that allows attachmentFig. 1. (A) Schematic representation of HHV-6A immediate–early A locus. Top
drawing represents HHV-6A genome including left and right direct repeats (DRL
and DRR) and immediate–early loci (IE-A and IE-B). Lower drawing represents
IE-A locus including repeat regions (R1–R3), orientation and approximate
position of major ORFs (arrows) and coding exons of key transcripts (IE1, IE2
and U95). U95 exon prediction is based on HHV-6B data. White circles denote
known transcription factor binding sites, including NF-κB/AP2/PEA3 (circa 28
copies in R3) and AP1 (2 overlapping putative binding sites upstream of R3 on
the sense strand). (B) Schematic representation of similarities between HHV-6A
and HCMV IE2 proteins. The two proteins share a significant identity in the C-
terminal domain. AD=activation domain; dimer.=dimerization domain; lower
brackets indicate HCMV IE2 regions required for DNA binding and
transactivation.of the transactivator to its target sequence within a gene
promoter, and an activation domain that promotes the trans-
cription of the target genes. For HHV-6A IE2, the activation and
DNA binding domains have not been defined yet, but clues
pertaining to the nature of its functional domains could perhaps
be deduced from studies of human cytomegalovirus (HCMV)
immediate–early protein IE2. HCMV like HHV-6 is a
betaherpesvirus and shares limited amino acid sequence
similarities, immunological cross-reactivity and overall gene
organization with HHV-6 (Lawrence et al., 1990; Neipel et al.,
1991; Yasukawa et al., 1993). HCMV gene UL122, encoding
for protein IE2, is a positional homologue of HHV-6 ORF U86
(Nicholas, 1994) and corresponds to the C-terminal portion of
HHV-6 IE2. The similarity between HCMV IE2 and the
carboxy-terminal region of HHV-6 IE2 is 45% (Nicholas,
1994). HCMV IE2 is a 86-kDa protein whose biological
functions are well defined and include transactivation of
heterologous promoters (Pizzorno et al., 1988), repression of
its own promoter (Hermiston et al., 1990), association with the
viral DNA replication compartment (Ahn et al., 1999), blocking
of cell cycle progression (Wiebusch and Hagemeier, 1999) and
modulation of apoptosis (Zhu et al., 1995).
Mapping studies have revealed that HCMV IE2 contains two
distinct acidic activation domains, one at the N terminus and
one at the C terminus (Fig. 1B). Both domains are required for
transactivation of most target reporter genes within the context
of wild-type IE2 (Pizzorno et al., 1991). The activator domains
of HCMV IE2 do not seem to fall within the conserved region
with HHV-6A IE2. However, minimal dimerization and DNA
binding domains have been identified in the HCMV IE2 region
having significant similarity with HHV-6 (Chiou et al., 1993).
In the present work, we used deletion mutants to map
functional transactivation domains of HHV-6A IE2 using
complex and minimal promoter sequences. This mapping
allowed us to determine that both the N-terminal and C-
terminal domains of IE2 are required for efficient transactiva-
tion, and that deletion of the C-terminal (1397–1466) tail of IE2
drastically reduces both transactivation and the nuclear patchy
distribution of IE2. Moreover, we determined that the ATF/CRE
binding site in the HHV-6A polymerase promoter is not
required for efficient transactivation of the promoter by IE2,
whereas the R3 repeat region of the putative immediate–early
promoter of HHV-6A strongly enhances IE2 transactivation of
this promoter. This and future characterization of IE2 should
provide a better understanding of this complex viral protein.
Furthermore, this study underscores important functional
differences between HCMV and HHV-6A IE2 proteins.
Results
Mapping of HHV-6A IE2 domains required for transactivation
The main function currently known of HHV-6A IE2 is to
promiscuously promote transcriptional activation (Gravel et al.,
2003). IE2 being a large protein, we generated various deletion
mutants in order to determine which domains are essential for
transactivation. We arbitrarily divided IE2 into three major
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repeat region (amino acids 721–944) and the C-terminal region
(amino acids 945–1466). We generated constructs lacking
either one or more of the large domains or smaller portions of
the protein for a more detailed mapping (Fig. 2A). All of the IE2
constructs have an N-terminal 6xHis tag for detection purposes.
The various constructs encoding for IE2 deletion mutants
were transfected into Molt-3 or HEK293T cells together with
luciferase reporter plasmids. Because promoter consensus
sequences could have an influence on which IE2 domains are
required for efficient transactivation, complex (multiple tran-
scription factor binding sequences) and minimal (single known
binding sequence) viral and cellular promoter reporters were
tested. The complex promoters tested were pLTR-Luc (a luci-
ferase reporter plasmid driven by the HIV LTR promoter),
pHHV-6 Pol-Luc (driven by theHHV-6A polymerase promoter),
pHHV-6 IE-Luc (HHV-6A immediate–early A locus putativeFig. 2. Mapping of HHV-6A IE2 domains required for transactivation in Molt-3
cells. (A) Deletion mutants of IE2 were generated by restriction digest or
mutagenesis of wild-type IE2. R1 is the SSRA/SSRD repeat region of IE2. (B)
HIV-1 LTR promoter transactivation by HHV-6A IE2. Molt-3 cells were
transfected by electroporation as described under materials and methods with
2 μg pLTR-Luc reporter construct and equal copy numbers of wild-type IE2 or
IE2 deletion mutant constructs (16 μg IE2, 16 μg IE2 2-1396, 16 μg IE2 2-1289,
16 μg IE2 2-1131, 13.8 μg IE2 2-1030, 12.3 μg IE2 2-719, 12.4 μg IE2 714–
1466, 11.3 μg IE2 945–1466 and 14.9 μg IE2 ΔR1). Empty vector pcDNA4
was used to adjust total DNA levels to 18 μg. Cells were lysed 48 h after
transfection. Transactivation of the pHHV-6 Pol-Luc reporter was quantified by
measurement of luciferase activity, expressed in fold transactivation relative to
control (pcDNA-transfected cells). Results were normalized for protein content
in each sample.promoter) and P2-1900 (driven by the human COX-2 promoter).
The minimal promoters tested were pCRE-Luc (a reporter
plasmid encoding for a luciferase transcript under control of a
cyclic AMP response element), pNFκB-Luc (under control of
multiple κ enhancer elements), pNFAT-TA-Luc (regulated by
nuclear factor for activated T cell consensus sequences), pAP1-
Luc (driven by multiple copies of Activator Protein 1 enhancer
element) and pTA-Luc (having a minimal TA promoter, TATA
box, as the only recognizable regulatory element). All of these
promoters are significantly activated by IE2, as reported by
Gravel et al. (Gravel et al., 2003) and this study.
We first performed transfection of promoter constructs in
Molt-3 T cells, a cell line efficiently infected by HHV-6. Wild-
type IE2 strongly transactivated the HIV-1 LTR promoter
construct (Fig. 2B). Surprisingly, none of the IE2 mutant
constructs had transactivating activity similar to wild-type IE2,
suggesting that the full-length protein is required for efficient
transactivation. Transfection efficiency being relatively low in T
cell lines, it was difficult to obtain consistent results with many
of the reporters tested. For these reasons, we switched to
HEK293T cells, which can be transfected more efficiently. Our
results indicate that transactivation of the HIV-1 LTR promoter
by wild-type IE2 and IE2 mutants follow closely what was
observed in Molt-3 T cells, suggesting no major differences
between the two cell lines. Results (Fig. 3) show that the wild-
type IE2 construct is able to strongly transactivate all of the
reporter constructs, including a minimal promoter comprised of
a TATA box. The N-terminal (IE2 2-719) or C-terminal (IE2
945–1466) domains have no significant transactivating activity
by themselves on any of the tested promoters. Likewise, mutants
lacking either the N-terminal (IE2 714–1466) or the C-terminal
(IE2 2-1030) domains are unable to transactivate most reporter
constructs. The only exception to this is the HHV-6A IE
promoter who is significantly transactivated by the IE2 2-1131
and 2-1030 mutants.
On the other hand, deletion of the central R1 repeat region
inhibited full transactivation of the reporters without completely
abolishing the activity of IE2. None of the promoters were
activated by IE2 ΔR1 as strongly as by wild-type IE2. Residual
transactivation activity (more than 20% of IE2 wild-type) was
observed with many (HHV-6A Pol, HHV-6A IE, LTR, COX-2,
NF-AT, TATA) but not all of the promoters (CRE, NF-κB,
AP1). On the whole, the results suggest that the complete IE2
protein is required for successful transactivation of all tested
promoters in HEK293T cells.
Interestingly, deletion of a short C-terminal stretch of 70
amino acids (1397–1466) drastically reduced IE2 activity on the
whole array of reporter constructs, either minimal or complex.
This region is not capable of transactivation by itself, as we have
shown that the C-terminal (945–1466) domain of IE2 is
transcriptionally inactive. In the light of these results, we further
investigated the impact of this small deletion on IE2 activity.
Expression of the IE2 mutants
The low transactivating activity of all IE2 deletion mutants
could potentially be caused by poor expression or defective
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mutants are properly expressed upon transfection in the
HEK293T cell line, we analyzed their relative expression by
western blotting using anti-His and anti-IE2 antibodies. As
shown in Fig. 4, all of the mutants are detected just as stronglyFig. 3. Mapping of HHV-6A IE2 domains required for transactivation in HEK293T
transfected as described under materials and methods with 1 μg pLTR-Luc reporte
constructs (7 μg IE2, 7 μg IE2 2-1396, 7 μg IE2 2-1289, 7 μg IE2 2-1131, 6.1 μg IE2
IE2 ΔR1). Cells were lysed 48 h after transfection. Transactivation of the pLTR-Luc
transactivation relative to control (pcDNA-transfected cells). Results are means±SD
protein content in each sample. (B–I) Transactivation of various promoters by HHV-6
for luciferase activity measurement as described above.or better than wild-type IE2. The enhanced expression of some
mutants relative to wild-type IE2 can be explained by the
shorter length of the encoded transcripts and proteins that lead
to increased transcriptional and translational efficiencies.
Mutant IE2 2-1030 could not be detected by the P6H8 anti-cells. (A) HIV-1 LTR promoter transactivation by IE2. HEK293T cells were
r construct and equal copy numbers of wild-type IE2 or IE2 deletion mutant
2-1030, 5.4 μg IE2 2-719, 5.4 μg IE2 714–1466, 5 μg IE2 945–1466 and 6.5 μg
reporter was quantified by measurement of luciferase activity, expressed in fold
from 3 distinct experiments of duplicate transfections and were normalized for
Awild-type IE2 or deletion mutants of IE2. Cells were transfected and processed
Fig. 3 (continued).
Fig. 4. Expression and detection of the IE2 mutants. HEK293T cells were
transfected with equal copy numbers of wild-type IE2 or IE2 deletion mutant
constructs (7 μg IE2, 7 μg IE2 2-1396, 7 μg IE2 2-1289, 7 μg IE2 2-1131, 6.1 μg
IE2 2-1030, 6.2 μg IE2 714–1466 and 6.5 μg IE2 ΔR1). Cells were harvested
48 h after transfection. Total lysates were analyzed by SDS–polyacrylamide gel
electrophoresis and probed using anti-His or anti-IE2 antibodies. Protein loading
was assessed with an anti-actin antibody.
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between amino acids 1030–1131 (Tomoiu et al., unpublished
results). Therefore, expression levels cannot account for the
lower transactivating activity of the IE2 mutants.
Nuclear distribution of the IE2 mutants
Because IE2 needs to reach the nucleus in order to act as a
transactivator, we had to confirm whether the inactive mutants
were properly transported to the nucleus. A computer search of
nuclear localization sequences using PSORT II (Nakai andHorton, 1999) has revealed four recognizable putative NLS in
HHV-6A IE2. Monopartite four-residue pattern sequences are
present at 355–358, 1046–1051 and 1210–1215, including
potential overlapping sequences. A bipartite putative NLS is
also detected at residues 423–439. To test the functionality of
these putative sequences we cloned in frame with GFP residues
423–440 (KKAHIRCRSVQKKKERSS, putative NLS residues
italicized) from the N-terminal domain and 1207–1215
(KKCKKKRPR) of the C-terminal domain of IE2. These
constructs were transfected into HEK293T cells and fluores-
cence assessed by microscopy. Both GFP-IE2 NLS fusion
proteins displayed intense and exclusively nuclear localization
patterns, as opposed to the diffuse, cytoplasmic distribution of
the control GFP protein (data not shown). We have therefore
identified at least two sequences from HHV-6A IE2 that act as
functional NLS and are most likely required for the proper
nuclear targeting of IE2.
We subsequently analyzed the intranuclear localization of
the different IE2 mutants by immunofluorescence. Transfected
HEK293T cells were prepared for microscopy and probed using
an anti-His antibody. In HHV-6A-infected cells, IE2 shows a
punctate pattern that evolves into large nuclear patches at 24–
48 h post-infection (Gravel et al., 2003). In transfected
HEK293T cells, wild-type IE2 also shows a patchy nuclear
pattern (Fig. 5). IE2 mutants 2-1030 and 2-1131, lacking the C-
terminal putative NLS at residues 1207–1215, have a diffuse
distribution that appears to be mostly cytoplasmic, probably due
to impaired nuclear shuttling of the mutant proteins. Unexpect-
edly, the IE2 ΔR1 construct (lacking the R1 region) also shows
a diffuse distribution even though it retains the C-terminal NLS.
It would thus appear that both the C-terminal NLS and the R1
repeat domain are important for proper nuclear localization of
IE2. However, the diminished transactivation activity of some
mutant IE2 proteins such as IE2 2-1396 and IE2 2-1289 does
Fig. 5. Nuclear distribution of the IE2 mutants. HEK293T cells were transfected with pcDNA4-IE2 or deletion mutant constructs and processed for
immunofluorescence as described under materials and methods. Left panels represent cells reacted with anti-His antibody (His-tagged IE2 in red) and second column
panels show same fields colored with DAPI nuclear stain (DAPI in blue). Localization of the IE2 protein versus nucleus is underscored in the merge panels, at 400×
total magnification. Right panels show representative cells at higher (1200×) magnification.
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terminal NLS and their localization pattern is still nuclear.
Interestingly, the IE2 2-1396 C-terminal tail mutant has a
visibly different punctate nuclear distribution. Unlike wild-type
IE2, IE2 2-1396 does not form large patches but numerous
small dot-like structures. Moreover, all of the mutants lacking
the C-terminal (1397–1466) tail also lose the patchy distribu-
tion of the wild-type protein. In contrast, the IE2 714–1466
construct (lacking the N-terminal region but not the C-terminaltail) does show the patchy distribution of wild-type IE2.
Because IE2 714–1466 has very little transactivating activity, it
appears that transactivation and patchy nuclear distribution of
IE2 are not correlated.
Transactivation of HHV-6A promoters
Because we have shown that IE2 is able to transactivate both
its own promoter and the viral polymerase promoter, we sought
Fig. 6. (A) HHV-6A Pol promoter transactivation by IE2. HEK293T cells were
transfected as described under materials and methods with 1 μg pHHV-6 Pol-
Luc or pHHV-6 PolΔATF-Luc reporter constructs and 7 μg of wild-type IE2.
Cells were lysed 48 h after transfection. Transactivation of the reporters was
quantified by measurement of luciferase activity, expressed in fold transactiva-
tion relative to control (pcDNA-transfected cells). Results are means±SD from
3 distinct experiments of duplicate transfections and were normalized for protein
content in each sample. IE2 expression and protein loading were assessed by
western blotting using anti-His, anti-IE2 and anti-actin antibodies. (B) HHV-6A
putative IE-A promoter transactivation by IE2. HEK293T cells were transfected
with 1 μg pHHV-6 IE-Luc or pHHV-6 IEΔR3-Luc reporter constructs and 7 μg
of wild-type IE2. Cells were processed for luciferase activity measurement as
described above.
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efficient transactivation. The HHV-6A Pol promoter has been
characterized before (Agulnick et al., 1994), and its only
recognizable transcription factor binding sequence is an ATF/
CRE-binding site. We looked into the importance of the ATF/
CRE site for IE2 transactivation by generating a mutant of the
pHHV-6 Pol-Luc reporter in which the ATF site was rendered
non-functional by directed mutagenesis. Fig. 6A shows that
transactivation of the pHHV-6 PolΔATF-Luc reporter is weaker
than that of wild-type Pol promoter. However, because basal
expression level of the mutant promoter is 10-fold lower than
that of the wild-type promoter, the overall relative transactiva-
tion of pHHV-6 PolΔATF-Luc is slightly stronger (105-fold)
than pHHV-6 Pol-Luc (62-fold). Therefore, the ATF/CRE
binding site is dispensable for IE2 transactivation of the HHV-
6A polymerase promoter. Interestingly, because the Pol
promoter is TATA-less (Agulnick et al., 1994), there must
exist other unidentified binding elements that promote IE2
transactivation of the viral promoter.
The HHV-6A immediate–early locus A promoter has been
tentatively identified as a sequence of circa 4 kbp between
ORFs U90 and U94 (Martin et al., 1991). Putative AP1
transcription factor binding sites have been identified in this
sequence. Another important element of the promoter is the R3
region, composed of 25–30 copies of approximately 105 bp
repeat units containing putative transcription factors AP2, NF-
κB and PEA3 binding sites. For HHV-6B, it has been shown
that the R3 repeats strongly enhance transcription of gene U95,
downstream of the IE promoter and on the opposite side of R3
from the IE-A locus (Takemoto et al., 2001). However, the R3
region has no significant effect on transactivation by HHV-6A
IE1, a IE-A protein encoded downstream of R3 on the reverse
strand (Martin et al., 1991). IE2 itself was shown to weakly
transactivate an IE-A promoter construct lacking the R3 repeats
(Gravel et al., 2003). We looked into the relevance of the R3
repeat region for IE2 transactivation by generating a pHHV-6
IE-Luc construct encoding for the full 4-kbp putative IE-A
promoter upstream of the luciferase gene. IE2 transactivation of
pHHV-6 IE-Luc was compared to that of pHHV-6 IEΔR3-Luc,
lacking the repeat region. Fig. 6B shows that full-length IE
promoter is much more efficiently transactivated by IE2 than
the promoter lacking the R3 region. This suggests that the AP2,
NF-κB and PEA3 binding sites may be important for IE2
transactivation of what likely constitutes its own promoter.
Discussion
The IE2 protein of HHV-6A is able to functionally
transactivate diverse promoters (Gravel et al., 2003; Martin et
al., 1991). To better characterize the IE2 transactivation
domains, we generated deletion mutants of various regions of
the protein and tested them for activation of both complex and
minimal promoter reporter constructs. Both the N-terminal and
the C-terminal domains of IE2 are required for efficient
transactivation of the tested reporters. The R1 SSRA/SSRD
repeat region is dispensable for transactivation on all comp-
lex and many minimal promoters tested, although its absence
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the transactivation of promoters by IE2 is as yet unclear, but its
strong basic charge and unstructured sequence suggest the
ability to non-specifically bind DNA and thus participate in the
attachment of IE2 to the promoter binding sites. Alternatively,
the R1 deletion may have an influence on global IE2 folding
and mask NLS sequences, change its ability to bind promoter
regions or recruit transcription factors.
The significant transactivating activity of deletion mutants
IE2 2-1131 and 2-1030 on the putative HHV-6A IE promoter
was observed for this promoter only. An explanation for this
residual activity may be linked to the numerous repeats (28
copies) of AP2, NF-κB and PEA3 binding sequences present
within this promoter. It is possible that these IE2 mutants exhibit
basal transactivating potential on minimal promoters but when
the number of regulatory elements is high, a cumulative effect
can be detected. This, however, does not explain why similar
results are not observed with the IE2 2-1396 and IE2 2-1289
mutants. Perhaps differences in protein folding of the various
mutants are responsible for the obtained results. It is of note that
even if these mutants are less efficiently transported to the
nucleus, as seen by immunofluorescence, because of a missing
NLS, cell fractionation assays have shown that a significant
fraction of these mutant proteins are still imported to the nucleus
and should be available for transactivation (data not shown).
The N-terminal NLS possibly plays a role in the import of
mutants missing the C-terminal NLS.
The sequence similarity between the C-terminal domains of
HHV-6A IE2 and HCMV IE2 could entail similar functions for
the two domains. The IE2 1397–1466 region aligns with
residues 486–568 of HCMV's 579 amino acid IE2 protein (Fig.
1B). The HHV-6A IE2 C-terminal tail includes a short motif
that is highly conserved among all betaherpesviruses, namely,
residues 1397–1417 (486–506 for HCMV IE2) (Chiou et al.,
1993). This motif forms part of the required transactivation,
autoregulation, dimerization and DNA binding domains of
HCMV IE2 (Chiou et al., 1993; Pizzorno et al., 1991). The
conservation of this element in HHV-6A may indicate an
important role in the IE2 protein activity. Accordingly, we
hypothesize a role in dimerization and DNA binding for the C-
terminal tail of HHV-6A IE2. Indeed, it has been shown that the
C-terminal domain of IE2 demonstrates some DNA binding
activity (Papanikolaou et al., 2002). The nuclear distribution of
wild-type IE2 suggests that there is some form of nuclear
aggregation or polymerization of the protein that is not present
with truncated IE2 2-1396. However, an unambiguous proof
that the punctate nuclear pattern of IE2 is linked to its ability to
bind DNA or to form protein dimers remains to be produced.
Interestingly, the 544–579 residues of HCMV IE2 have been
defined as an acidic activator domain (Pizzorno et al., 1991).
Similarity between HCMV IE2 544–579 and the corresponding
HHV-6A IE2 residues (1456–1466) is virtually non-existent, so
we can surmise that HHV-6A IE2 lacks the C-terminal acidic
activator domain present in its HCMV homolog. Mammalian
one-hybrid tests with the C-terminal tail of HHV-6A IE2 did
confirm that this protein fragment cannot act as a transcriptional
activator (data not shown).Another important functional difference between the IE2
proteins of HHV-6A and HCMV is here underscored. Although
it has been shown that HCMV IE2 is able to downregulate its
promoter through binding to a cis repression signal near the
transcription start site (Cherrington et al., 1991; Hermiston et
al., 1990; Pizzorno et al., 1988), HHV-6A IE2 upregulates the
putative viral IE promoter in our system. Moreover, in infected
cells the HHV-6A IE2 transcript is increasingly expressed
throughout the whole infectious process (Gravel et al., 2003).
Thus, downregulation of its own transcript does not appear to be
a characteristic of HHV-6A IE2. This may in part be explained
by the fact that the HCMV cis repression signal is not conserved
in HHV-6A. Indeed, although HCMV and HHV-6 share high
levels of genetic identity, both viruses have found different
ways to exploit similar genetic elements. Table 1 presents a
summary of phenotypical and functional differences between
HCMV and HHV-6 variants A and B.
Although the ATF/CRE binding site within the HHV-6A
polymerase promoter is required for transactivation of the viral
promoter upon infection (Agulnick et al., 1994), its absence
does not reduce transactivation of the polymerase promoter by
IE2 (this study). A similar observation was made about the
human CD4 promoter. HHV-6A infection can induce CD4 gene
transcription via an ATF/CRE binding site within the CD4
promoter, but IE2 transactivates equally well the wild-type
promoter and a mutant CD4 promoter lacking the ATF/CRE
binding site (Flamand et al., 1998). This suggests that other viral
proteins are likely to contribute to the CD4 and HHV-6A
polymerase transcriptional activation.
Our analysis of IE2 activation of multiple promoters failed to
pinpoint specific transcription binding sequences uncondition-
ally required for efficient transactivation. IE2 is able to
transactivate via the TATA box and the basal transcriptional
machinery but can also activate promoters that are TATA-less
(such as the HHV-6A polymerase promoter) through yet
unidentified transcription factor binding sites. Although the
array of promoters efficiently transactivated by IE2 in vitro is
extensive, this does not imply that IE2 will also activate all of
those cellular promoters in vivo. Availability of a specific
promoter is determined by chromatin remodeling, and tran-
scription factors have access to only a fraction of the cellular
promoters at any moment. Interestingly, we have demonstrated
that upon HHV-6A infection, IE2 localizes in the vicinity of
promyelocytic leukemia-associated nuclear bodies (PML-NB)
(Tomoiu et al., unpublished results). PML-NB have a role in
chromatin dynamics and are thought to participate in the
repression of gene expression, as reviewed in (Everett, 2006).
Upon HHV-6 infection, the nuclear PML-NB distribution is
altered (Gravel et al., 2002), and a consequence of this alteration
may be greater chromatin availability to viral transactivators
such as IE2.
Promoter transactivation by HHV-6A IE2 is possibly the
result of several non-exclusive mechanisms of action. First, the
IE2 protein may bind directly to transcription factor binding
sites within promoters and recruit transcriptional units; second,
the IE2 protein may act as a co-activator by interacting with
other transcription factors via protein–protein interaction and
Table 1
Summary of phenotypical and functional differences between HCMV, HHV-6A and HHV-6B
Function HCMV HHV-6A HHV-6B
Pathogenesis
In vitro cell tropism Skin or lung fibroblasts,
endothelial cells
T lymphocytes,
monocytes, neural cells
(oligodendrocytes,
astrocytes, neurons)
T lymphocytes, monocytes
Primary infection Usually asymptomatic,
mononucleosis
Asymptomatic?
(encephalitis, meningitis,
multiple sclerosis?)
Exanthema subitum,
febrile seizures
Congenital infection Neurological damage Unknown consequences Unknown consequences
Immunocompromised hosts Organ damage
and failure
Unknown Encephalitis, graft versus host
disease, delayed platelet engraftment
Virus–cell interactions
Host genome
integration
No Yes (infrequent) Yes (infrequent)
Effect on PML-NB
upon infection
Dispersal Limited aggregation Aggregation
IE2 protein
Transactivation Yes Yes Unknown
Autoregulation Yes No Unknown
Transrepression Yes No Unknown
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affect post-translational modifications, such as phosphorylation
or ubiquitination, leading to increased or more sustained activity
of transcription factors; and fourth, IE2 may activate the
expression of other genes involved in transactivation processes
(Wang et al., 1994). The precise mechanisms by which IE2
transactivates promoters remain unknown. The ability of IE2 to
transactivate multiple promoters having distinct transcription
factor responsive elements could suggest that the HHV-6A IE2
protein does not bind a specific DNA consensus sequence
directly, but rather interacts with regulatory proteins common to
many transcriptional units. However, the existing evidence that
the C-terminal domain of HHV-6A IE2 is able to bind the
putative IE-A promoter (Papanikolaou et al., 2002) and that its
homologue HCMV IE2 also has a DNA binding domain (Chiou
et al., 1993) suggests that HHV-6A IE2 acts as a transcriptional
enhancer through DNA binding followed by the activation or
recruitment of transcriptional unit complexes. More character-
ization of the functional domains of IE2 is required for a better
understanding of the mechanisms underlying the complex
relationship between the viral protein and its host transcriptional
machinery.
Materials and methods
Virus and cell lines
The HSB-2 and Molt-3 leukemia human T cell lines were
cultured in MegaCell RPMI-1640 medium supplemented with
10% foetal bovine serum (Sigma-Aldrich Canada, Oakville,
ON) and M-plasmocin (InvivoGen, San Diego, CA) to prevent
mycoplasma contamination. HEK293T human epithelial kid-
ney cell line was cultured in MegaCell Dulbecco's modified
Eagle's medium (Sigma-Aldrich) supplemented with 3% foetal
bovine serum and M-plasmocin, and passaged every two days.HHV-6A (GS strain) was propagated in HSB-2 cells as
previously described (Flamand et al., 1991).
Plasmid generation
For the transactivation assays, complete (except for the initial
methionine) wild-type HHV-6A IE2 was PCR amplified from
pBK-IE2A (Gravel et al., 2003) (forward primer 5′-aggtacc
GGA GCC AGC AAA ACC-3′; reverse primer 5′-cctcgagg
TTA ACA TTT TGA AAG TGT AC-3′; adapters not
homologous with viral sequence are indicated by lower script,
KpnI and XhoI restriction sites are italicized), TOPO-ligated
into pCR4 cloning vector (Invitrogen, Carlsbad, CA) then
subcloned in-frame into KpnI/XhoI digested pcDNA4/His-
MaxA vector (Invitrogen) to yield pcDNA4-IE2.
In order to map the transactivation domains of IE2, the
following constructs were generated by single-base mutagen-
esis following the QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) instructions. Wild-type plasmid
pcDNA4-IE2 was mutated to pcDNA4-IE2 2-1396 using stop-
codon mutagenic primer 5′-CAT GAT CTA TTT ACG TGA
CAT TCG GAC GTA AAG-3′ and its complementary
oligonucleotide (mutated base is italicized). Constructs
pcDNA4-IE2 2-1289 and pcDNA4-IE2 2-1131 were also
generated by single-base mutagenesis of pcDNA4-IE2 using,
respectively, primers 5′-GAG AGC ATT TGA ATA CTA ACA
GAT CCC CAA AAA ACC-3′, 5′-CAG ATT CAA AAC ACT
AAA CTA CAA ACA TGT CTT CAG-3′ and their comple-
mentary oligonucleotides. Construct pcDNA4-IE2 2-1030 was
generated by XbaI digesting pcDNA4-IE2 into 3 fragments and
ligating back together the two larger fragments (5854 and 2430
pb). Construct pcDNA4-IE2 945–1466 was generated by PCR
amplification of the 3′ segment of IE2 from the pBK-IE2A
template, using forward primer 5′-ggatatc GCT GAG GCA
GAT TTATTG C-3′ and reverse primer 5′-cctcgagg TTA ACA
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are italicized). The PCR amplicon was TOPO-ligated into pCR4
cloning vector then subcloned in-frame into EcoRV/XhoI
digested pcDNA4/HisMaxA vector. Construct pcDNA4-IE2
2-719 was created by PCR amplification of the 5′ segment of
IE2 from the pBK-IE2A template, using forward primer 5′-
aggtacc GGA GCC AGC AAA ACC-3′ and reverse primer
FLAL259 5′-cgatatc ATG GTG CAA CTT TTA CTC AG-3′
(KpnI and EcoRV restriction sites are italicized). Resulting
DNA was TOPO-ligated into pCR4 cloning vector then
subcloned in-frame into KpnI/EcoRV digested pcDNA4/
HisMaxA vector. The same amplicon was subcloned in-frame
into KpnI/EcoRV digested pcDNA4-IE2 945–1466 to yield
construct pcDNA4-IE2 ΔR1 (2–719+945–1466). Finally,
deletion mutant pcDNA4-IE2 714-1466 was generated by
PCR amplification on the pBK-IE2A template, using forward
primer 5′-aggtacc GAG TAA AAG TTG CAC CAT G-3′ and
reverse primer 5′-cctcgagg TTA ACA TTT TGA AAG TGT
AC-3′ (KpnI and XhoI restriction sites are italicized). Amplicon
was TOPO-ligated into pCR4 cloning vector then subcloned in-
frame into KpnI/XhoI digested pcDNA4/HisMaxA vector.
Luciferase reporter construct pHHV-6 Pol-Luc was gener-
ated by PCR amplification on genomic DNA from HHV-6A-
infected HSB-2 cells, using forward primer 5′-tatggtacc GAA
GCT AAA ATT GCT ACK AAT ACR CC-3′ and reverse
primer 5′-cgacccggg CAC GCT TCT TCT ACA TTT ACA
CTC TT-3′ (KpnI and SmaI restriction sites are italicized).
Amplicon was TOPO-ligated into pCR4 cloning vector then
subcloned into KpnI/SmaI digested pGL3-Basic vector (Pro-
mega, Madison, WI). ATF site mutant construct pHHV-6
PolΔATF-Luc was generated by directed mutagenesis on the
pHHV-6 Pol-Luc template using mutagenic primers 5′-GGG
TAT GGC TGT TAA CAG TGG GCA AG-3′ and its
complementary oligonucleotide (mutated base are italicized).
Construct pHHV-6 IE was generated by PCR amplification of
the putative IE-A promoter sequence from pR56 (kindly
provided by Dr. M. E. D. Martin) (Martin et al., 1991) using
forward primer 5′-TTG ACT TAC CAG ACT GCA ACG-3′
and reverse primer 5′-TTC CTA CCC AAG CGG GTTAG-3′.
Resulting DNA was TOPO-ligated into pCR4 cloning vector,
EcoRI digested and ligated into pcDNA3.1 (Invitrogen),
extracted using XhoI and HindIII, and ligated into XhoI/Hin-
dIII digested pGL3-Basic vector.
Transfections and luciferase assays
Transfections of HEK293T were performed using the
calcium phosphate precipitation procedures. Cells were plated
at 200 000 cells/well (6-well plate) the day prior to transfection.
Cells were transfected with 1 μg of reporter plasmid and up to
7 μg of expression vector per well and brought to a total of 8 μg
of DNA per well for each condition with the pcDNA4 control
plasmid. Cells were lysed 48 h after transfection. Transactiva-
tion was evaluated using luciferase reporter constructs, coding
for the luciferase gene driven by various promoters. Luciferase
activity was measured on an MLX Microtiter plate lumin-
ometer (Dynex Technologies, Chantilly, VA). The valuesobtained are means of 3 distinct experiments performed in
duplicate and were normalized for protein concentration in each
sample, as determined by a BCA colorimetric assay (Pierce,
Rockford, IL).
Molt-3 cells were transfected by electroporation using a
Gene Pulser apparatus and capacitance extender (Bio-Rad
Laboratories, Hercules, CA). Briefly, 18 μg total DNA was
added to 107 cells in 400 μL RPMI medium. Cells were pulsed
at 0.25 kV with a 960-μF capacitance in a 0.4-cm gap
electroporation cuvette (Bio-Rad Laboratories). Cells were
transferred into 10 mL culture medium and lysed after 48 h of
growth. Transactivation of reporter constructs was assayed as
described above.
The following luciferase reporter plasmids have been tested
for IE2 transactivation. Constructs pCRE-Luc, pNFκB-Luc,
pNFAT-TA-Luc, pAP1-Luc and pTA-Luc were purchased from
Clontech (Mountain View, CA). Construct pLTR-Luc was
kindly provided by Dr. M. Tremblay; P2-1900 as previously
described (Iniguez et al., 2000) was kindly provided by Dr. M.
Fresno); pHHV-6 IEΔR3-Luc was previously described (Gravel
et al., 2003). Generation of pHHV-6 IE-Luc, pHHV-6 Pol-Luc
and pHHV-6 PolΔATF-Luc was detailed above.
Western blotting
For western blot analysis, cells were washed in PBS, lysed in
an appropriate volume of Laemmli buffer and boiled. Samples
were electrophoresed through an SDS–polyacrylamide gel,
transferred to polyvinylidene fluoride membranes and blotted
for 1 h at room temperature. After three 10-min washes with
TBST, the blots were incubated with horseradish peroxidase-
conjugated secondary antibodies for 1 h. The blots were then
washed with TBST and the proteins were visualized with
enhanced chemiluminescence (Perkin-Elmer, Boston, MA)
using a PhosphorImager system (Fuji Medical Systems,
Stamford, CT). Primary antibodies used were P6H8 mouse
anti-HHV-6A IE2 as previously described (Arsenault et al.,
2003), mouse anti-His (Amersham Biosciences, Baie d'Urfé,
QC) and mouse anti-actin (Santa Cruz Biotechnology, Santa
Cruz, CA).
Immunofluorescence
HEK293T cells were transfected for 48 h, fixed with cold
(−20 °C) acetone and incubated with the antibodies described
hereafter. IE2 expression was detected with a mouse anti-His
monoclonal antibody (Amersham Biosciences), followed by a
rabbit anti-mouse antibody coupled to the Alexa 568 red dye
(Molecular Probes, Eugene, OR). Nuclei were stained by
incubating the cells with a 1:1000 solution of 4′,6-diamidino-2-
phenylindole (DAPI; Molecular Probes) nucleic acid stain for
10 min. Images were captured by a CoolSNAP HQ camera
mounted on an Olympus BX-51 upright microscope (Olympus
America, Melville, NY) using a 40× Uplan Apo objective and
568 nm (red dye, His) and 461 nm (blue dye, DAPI) filters, and
processed with ImagePro 4.5.1 software (Media Cybernetics,
Silver Spring, MD).
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